0L49.LSE SCYNEXIS, Inc.
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Is 0L49.LSE undervalued?
Graham numberThe Graham number of SCYNEXIS, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
SCYNEXIS, Inc. fundamental analysis
No fundamental analysis for SCYNEXIS, Inc. yet.
SCYNEXIS, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About SCYNEXIS, Inc.
SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS…
Full company profileFinancial statements of SCYNEXIS, Inc. are not available yet.
SCYNEXIS, Inc. dividends
SCYNEXIS, Inc. has not paid dividends in the last 4 fiscal years.
Last stock split: 0.125:1 on Jun 1, 2026.
Who owns SCYNEXIS, Inc.
- Insiders 2.05%
- Institutions 62.10%
- Public & others 35.85%
- Free float 7.35M
SCYNEXIS, Inc. company profile
- Company name
- SCYNEXIS, Inc.
- Ticker
- 0L49.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 18
- Fiscal year end
- December
- Address
- 1 Evertrust Plaza, Jersey City, NJ, United States, 07302-6548
- Phone
- 201 884 5485
- Website
- scynexis.com
About SCYNEXIS, Inc.
SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
SCYNEXIS, Inc. management
6- Dr. David Gonzalez Angulo M.D.CEO, President & Director · born 1965
- Mr. Scott Sukenick J.D.Chief Legal Officer & Corporate Secretary · born 1978
- Mr. Sanjay S. Subramanian M.B.A., M.S.Chief Financial Officer · born 1976
- Ms. Daniella GiganteVice President of Human Resources & Information Technology
- Dr. Todd Minga M.D.Senior Vice President of Research & Development
- Dr. Rossana Ferrara-Pontoriero Ph.D.Senior Vice President of Business Development & Portfolio Management